troglitazone has been researched along with Myositis, Multiple in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujibayashi, K | 1 |
| Nagasaka, S | 1 |
| Itabashi, N | 1 |
| Kawakami, A | 1 |
| Nakamura, T | 1 |
| Kusaka, I | 1 |
| Ishikawa, S | 1 |
| Saito, T | 1 |
1 other study available for troglitazone and Myositis, Multiple
| Article | Year |
|---|---|
Troglitazone efficacy in a subject with glucocorticoid-induced diabetes.
Topics: Aged; C-Peptide; Chromans; Diabetes Mellitus; Female; Glucocorticoids; Humans; Hypoglycemic Agents; | 1999 |